These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29759120)

  • 21. Therapeutics in rheumatology and the kidney.
    Harty T; O'Shaughnessy M; Harney S
    Rheumatology (Oxford); 2023 Mar; 62(3):1009-1020. PubMed ID: 35951751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients].
    Gómez Reino J; Loza E; Andreu JL; Balsa A; Batlle E; Cañete JD; Collantes Estévez E; Fernández Carballido C; Fernández Sueiro JL; García de Vicuña R; González-Álvaro I; González Fernández C; Juanola X; Linares LF; Marenco JL; Martín Mola E; Moreno Ramos M; Mulero Mendoza J; Muñoz Fernández S; Queiro R; Richi Alberti P; Sanz J; Tornero Molina J; Zarco Montejo P; Carmona L;
    Reumatol Clin; 2011; 7(5):284-98. PubMed ID: 21925444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical treatment of adolescents with rheumatic disease.
    Hollister JR
    Adolesc Med; 1998 Feb; 9(1):163-70, vii. PubMed ID: 10961259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.
    Peponis V; Kyttaris VC; Chalkiadakis SE; Bonovas S; Sitaras NM
    Lupus; 2010 May; 19(6):675-82. PubMed ID: 20144965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
    Woodworth T; Furst DE; Alten R; Bingham CO; Yocum D; Sloan V; Tsuji W; Stevens R; Fries J; Witter J; Johnson K; Lassere M; Brooks P
    J Rheumatol; 2007 Jun; 34(6):1401-14. PubMed ID: 17552067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Institute of Rheumatology and progress of antirheumatic therapy].
    Sigidin IaA
    Vestn Ross Akad Med Nauk; 1998; (12):7-9. PubMed ID: 9987950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology.
    Ferraccioli G; De Santis M; Tolusso B
    Pharmacogenomics; 2004 Dec; 5(8):1107-16. PubMed ID: 15584877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
    El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
    Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspects of allergy in rheumatology.
    Spoerl D; Scherer K; Tyndall A
    Clin Exp Rheumatol; 2011; 29(3):560-6. PubMed ID: 21418783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antimalarial preparations in rheumatology: new prospects].
    Nasonov EL
    Ter Arkh; 1996; 68(1):67-71. PubMed ID: 8644039
    [No Abstract]   [Full Text] [Related]  

  • 31. The Corrona US registry of rheumatic and autoimmune diseases.
    Kremer JM
    Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S96-S99. PubMed ID: 27762197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care.
    Pincus T; Braun J; Kavanaugh A; Smolen JS
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-1. PubMed ID: 25365080
    [No Abstract]   [Full Text] [Related]  

  • 33. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current world literature.
    Curr Opin Rheumatol; 2013 May; 25(3):398-409. PubMed ID: 23528992
    [No Abstract]   [Full Text] [Related]  

  • 35. [Evidence based medicine in rheumatology].
    Gause A; Raspe HH
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract]   [Full Text] [Related]  

  • 36. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.
    Schreiber K; Frishman M; Russell MD; Dey M; Flint J; Allen A; Crossley A; Gayed M; Hodson K; Khamashta M; Moore L; Panchal S; Piper M; Reid C; Saxby K; Senvar N; Tosounidou S; van de Venne M; Warburton L; Williams D; Yee CS; Gordon C; Giles I;
    Rheumatology (Oxford); 2023 Apr; 62(4):e89-e104. PubMed ID: 36318967
    [No Abstract]   [Full Text] [Related]  

  • 37. [Chinese expert consensus on diagnosis and treatment of antirheumatic drug-induced liver injury(2024)].
    ; ; ; ; ; ; ;
    Zhonghua Nei Ke Za Zhi; 2024 Aug; 63(8):743-761. PubMed ID: 39069863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of infliximab in academic rheumatology practice: an audit of early clinical experience.
    Fitzcharles MA; Clayton D; Ménard HA
    J Rheumatol; 2002 Dec; 29(12):2525-30. PubMed ID: 12465146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use.
    Stach CM; Sloan VS; Woodworth TG; Kilgallen B; Furst DE
    Drug Saf; 2019 Dec; 42(12):1499-1506. PubMed ID: 31696432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does low-dose methotrexate deserve more respect from clinicians?
    Luu B; Rodway GW
    JAAPA; 2017 May; 30(5):12-15. PubMed ID: 28441215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.